A cholinergic agonist induces cerebral hyperemia in isoflurane- but not pentobarbital-anesthetized dogs

M. K. Sturaitis, L. E. Moore, Jeffrey Kirsch, R. W. McPherson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We tested whether the cerebral blood flow (CBF) response to the cholinergic agonist oxotremorine (OXO) is affected by the choice of anesthetics in dogs. We studied two anesthetics, pentobarbital and isoflurane, which produce similar levels of cerebral metabolic depression but have opposing effects on CBF. We also tested the contribution of nitric oxide (NO, or a NO-containing compound) in mediating the CBF response to OXO by determining whether NO synthase inhibition with N(ω)-nitro-L-arginine methyl ester (L-NAME) would attenuate OXO-induced hyperemia in both anesthetic groups. CBF (microspheres) was measured before and after OXO administration (50 μg · kg-1 · min-1 intravenously [IV] for 10 min). Animals were divided randomly to receive OXO alone (n = 10) or L-NAME (40 mg/kg IV) followed by OXO (n = 10). Within each group, half of the animals received pentobarbital anesthesia (30 mg/kg IV) and half received isoflurane (1.4% end-tidal). In pentobarbital-anesthetized animals OXO produced no change in blood flow to cerebrum, caudate, diencephalon, neurohypophysis, or cerebellum in the absence (e.g., cerebrum 37 ± 2 vs 42 ± 5 mL/min/100 g) or presence of L-NAME (e.g., cerebrum, 29 ± 4 vs 30 ± 3 mL · min-1 · 100 g-1). In isoflurane-anesthetized animals, however, blood flow to forebrain regions increased after OXO (e.g., cerebrum 108 ± 10 vs 232 ± 15 mL · min-1 · 100 g-1; P <0.05) without alteration in oxygen consumption in cerebrum (CMRO2) or blood flow to hindbrain regions. In isoflurane-anesthetized animals, L-NAME decreased baseline blood flow to cerebrum, caudate, diencephalon, cerebellum, and neurohypophysis (P <0.05). L-NAME prevented OXO-induced hyperemia in caudate and diencephalon but not in cerebrum (51 ± 5 vs 81 ± 13 mL · min-1 · 100 g-1). We conclude that anesthetics modulate cholinergic-induced cerebral hyperemia. The mechanism for OXO- induced hyperemia is partially due to stimulation of NO synthase and is not associated with an increase in CMRO2 in cerebrum.

Original languageEnglish (US)
Pages (from-to)876-883
Number of pages8
JournalAnesthesia and Analgesia
Volume78
Issue number5
StatePublished - 1994
Externally publishedYes

Fingerprint

Oxotremorine
Cholinergic Agonists
Isoflurane
Hyperemia
Pentobarbital
Cerebrum
Dogs
Cerebrovascular Circulation
NG-Nitroarginine Methyl Ester
Diencephalon
Anesthetics
Posterior Pituitary Gland
Nitric Oxide Synthase
Cerebellum
Rhombencephalon
Prosencephalon
Microspheres
Oxygen Consumption
Cholinergic Agents
Nitric Oxide

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

A cholinergic agonist induces cerebral hyperemia in isoflurane- but not pentobarbital-anesthetized dogs. / Sturaitis, M. K.; Moore, L. E.; Kirsch, Jeffrey; McPherson, R. W.

In: Anesthesia and Analgesia, Vol. 78, No. 5, 1994, p. 876-883.

Research output: Contribution to journalArticle

@article{ae48047d5d374522b2054bc6bb19a509,
title = "A cholinergic agonist induces cerebral hyperemia in isoflurane- but not pentobarbital-anesthetized dogs",
abstract = "We tested whether the cerebral blood flow (CBF) response to the cholinergic agonist oxotremorine (OXO) is affected by the choice of anesthetics in dogs. We studied two anesthetics, pentobarbital and isoflurane, which produce similar levels of cerebral metabolic depression but have opposing effects on CBF. We also tested the contribution of nitric oxide (NO, or a NO-containing compound) in mediating the CBF response to OXO by determining whether NO synthase inhibition with N(ω)-nitro-L-arginine methyl ester (L-NAME) would attenuate OXO-induced hyperemia in both anesthetic groups. CBF (microspheres) was measured before and after OXO administration (50 μg · kg-1 · min-1 intravenously [IV] for 10 min). Animals were divided randomly to receive OXO alone (n = 10) or L-NAME (40 mg/kg IV) followed by OXO (n = 10). Within each group, half of the animals received pentobarbital anesthesia (30 mg/kg IV) and half received isoflurane (1.4{\%} end-tidal). In pentobarbital-anesthetized animals OXO produced no change in blood flow to cerebrum, caudate, diencephalon, neurohypophysis, or cerebellum in the absence (e.g., cerebrum 37 ± 2 vs 42 ± 5 mL/min/100 g) or presence of L-NAME (e.g., cerebrum, 29 ± 4 vs 30 ± 3 mL · min-1 · 100 g-1). In isoflurane-anesthetized animals, however, blood flow to forebrain regions increased after OXO (e.g., cerebrum 108 ± 10 vs 232 ± 15 mL · min-1 · 100 g-1; P <0.05) without alteration in oxygen consumption in cerebrum (CMRO2) or blood flow to hindbrain regions. In isoflurane-anesthetized animals, L-NAME decreased baseline blood flow to cerebrum, caudate, diencephalon, cerebellum, and neurohypophysis (P <0.05). L-NAME prevented OXO-induced hyperemia in caudate and diencephalon but not in cerebrum (51 ± 5 vs 81 ± 13 mL · min-1 · 100 g-1). We conclude that anesthetics modulate cholinergic-induced cerebral hyperemia. The mechanism for OXO- induced hyperemia is partially due to stimulation of NO synthase and is not associated with an increase in CMRO2 in cerebrum.",
author = "Sturaitis, {M. K.} and Moore, {L. E.} and Jeffrey Kirsch and McPherson, {R. W.}",
year = "1994",
language = "English (US)",
volume = "78",
pages = "876--883",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A cholinergic agonist induces cerebral hyperemia in isoflurane- but not pentobarbital-anesthetized dogs

AU - Sturaitis, M. K.

AU - Moore, L. E.

AU - Kirsch, Jeffrey

AU - McPherson, R. W.

PY - 1994

Y1 - 1994

N2 - We tested whether the cerebral blood flow (CBF) response to the cholinergic agonist oxotremorine (OXO) is affected by the choice of anesthetics in dogs. We studied two anesthetics, pentobarbital and isoflurane, which produce similar levels of cerebral metabolic depression but have opposing effects on CBF. We also tested the contribution of nitric oxide (NO, or a NO-containing compound) in mediating the CBF response to OXO by determining whether NO synthase inhibition with N(ω)-nitro-L-arginine methyl ester (L-NAME) would attenuate OXO-induced hyperemia in both anesthetic groups. CBF (microspheres) was measured before and after OXO administration (50 μg · kg-1 · min-1 intravenously [IV] for 10 min). Animals were divided randomly to receive OXO alone (n = 10) or L-NAME (40 mg/kg IV) followed by OXO (n = 10). Within each group, half of the animals received pentobarbital anesthesia (30 mg/kg IV) and half received isoflurane (1.4% end-tidal). In pentobarbital-anesthetized animals OXO produced no change in blood flow to cerebrum, caudate, diencephalon, neurohypophysis, or cerebellum in the absence (e.g., cerebrum 37 ± 2 vs 42 ± 5 mL/min/100 g) or presence of L-NAME (e.g., cerebrum, 29 ± 4 vs 30 ± 3 mL · min-1 · 100 g-1). In isoflurane-anesthetized animals, however, blood flow to forebrain regions increased after OXO (e.g., cerebrum 108 ± 10 vs 232 ± 15 mL · min-1 · 100 g-1; P <0.05) without alteration in oxygen consumption in cerebrum (CMRO2) or blood flow to hindbrain regions. In isoflurane-anesthetized animals, L-NAME decreased baseline blood flow to cerebrum, caudate, diencephalon, cerebellum, and neurohypophysis (P <0.05). L-NAME prevented OXO-induced hyperemia in caudate and diencephalon but not in cerebrum (51 ± 5 vs 81 ± 13 mL · min-1 · 100 g-1). We conclude that anesthetics modulate cholinergic-induced cerebral hyperemia. The mechanism for OXO- induced hyperemia is partially due to stimulation of NO synthase and is not associated with an increase in CMRO2 in cerebrum.

AB - We tested whether the cerebral blood flow (CBF) response to the cholinergic agonist oxotremorine (OXO) is affected by the choice of anesthetics in dogs. We studied two anesthetics, pentobarbital and isoflurane, which produce similar levels of cerebral metabolic depression but have opposing effects on CBF. We also tested the contribution of nitric oxide (NO, or a NO-containing compound) in mediating the CBF response to OXO by determining whether NO synthase inhibition with N(ω)-nitro-L-arginine methyl ester (L-NAME) would attenuate OXO-induced hyperemia in both anesthetic groups. CBF (microspheres) was measured before and after OXO administration (50 μg · kg-1 · min-1 intravenously [IV] for 10 min). Animals were divided randomly to receive OXO alone (n = 10) or L-NAME (40 mg/kg IV) followed by OXO (n = 10). Within each group, half of the animals received pentobarbital anesthesia (30 mg/kg IV) and half received isoflurane (1.4% end-tidal). In pentobarbital-anesthetized animals OXO produced no change in blood flow to cerebrum, caudate, diencephalon, neurohypophysis, or cerebellum in the absence (e.g., cerebrum 37 ± 2 vs 42 ± 5 mL/min/100 g) or presence of L-NAME (e.g., cerebrum, 29 ± 4 vs 30 ± 3 mL · min-1 · 100 g-1). In isoflurane-anesthetized animals, however, blood flow to forebrain regions increased after OXO (e.g., cerebrum 108 ± 10 vs 232 ± 15 mL · min-1 · 100 g-1; P <0.05) without alteration in oxygen consumption in cerebrum (CMRO2) or blood flow to hindbrain regions. In isoflurane-anesthetized animals, L-NAME decreased baseline blood flow to cerebrum, caudate, diencephalon, cerebellum, and neurohypophysis (P <0.05). L-NAME prevented OXO-induced hyperemia in caudate and diencephalon but not in cerebrum (51 ± 5 vs 81 ± 13 mL · min-1 · 100 g-1). We conclude that anesthetics modulate cholinergic-induced cerebral hyperemia. The mechanism for OXO- induced hyperemia is partially due to stimulation of NO synthase and is not associated with an increase in CMRO2 in cerebrum.

UR - http://www.scopus.com/inward/record.url?scp=0028230496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028230496&partnerID=8YFLogxK

M3 - Article

C2 - 8160984

AN - SCOPUS:0028230496

VL - 78

SP - 876

EP - 883

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 5

ER -